Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

Irene Brana; Martin Forster; Antonio López-Pousa; Bernard Doger; Patricia Roxburgh; Pawan Bajaj; Daniela Portillo; Vanesa Quiroga; Matthew Krebs; Christian Mueller; Frederic Triebel

doi:10.1200/JCO.2021.39.15_suppl.6028

Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

Irene Brana, Martin Forster, Antonio López-Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Daniela Portillo, Vanesa Quiroga, Matthew Krebs, Christian Mueller, Frederic Triebel

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	6028
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_suppl.6028
Publication status	Published - 20 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2021.39.15_suppl.6028

Cite this

Brana, I., Forster, M., López-Pousa, A., Doger, B., Roxburgh, P., Bajaj, P., Portillo, D., Quiroga, V., Krebs, M., Mueller, C., & Triebel, F. (2021). Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma. Journal of Clinical Oncology, 39, 6028. https://doi.org/10.1200/JCO.2021.39.15_suppl.6028

@article{16dedc214f4c4a0b9ea4cad293546188,

title = "Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.",

author = "Irene Brana and Martin Forster and Antonio L{\'o}pez-Pousa and Bernard Doger and Patricia Roxburgh and Pawan Bajaj and Daniela Portillo and Vanesa Quiroga and Matthew Krebs and Christian Mueller and Frederic Triebel",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15_suppl.6028",

language = "English",

volume = "39",

pages = "6028",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Brana, I, Forster, M, López-Pousa, A, Doger, B, Roxburgh, P, Bajaj, P, Portillo, D, Quiroga, V, Krebs, M, Mueller, C & Triebel, F 2021, 'Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.', Journal of Clinical Oncology, vol. 39, pp. 6028. https://doi.org/10.1200/JCO.2021.39.15_suppl.6028

Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma. / Brana, Irene; Forster, Martin; López-Pousa, Antonio et al.
In: Journal of Clinical Oncology, Vol. 39, 20.05.2021, p. 6028.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

AU - Brana, Irene

AU - Forster, Martin

AU - López-Pousa, Antonio

AU - Doger, Bernard

AU - Roxburgh, Patricia

AU - Bajaj, Pawan

AU - Portillo, Daniela

AU - Quiroga, Vanesa

AU - Krebs, Matthew

AU - Mueller, Christian

AU - Triebel, Frederic

PY - 2021/5/20

Y1 - 2021/5/20

U2 - 10.1200/JCO.2021.39.15_suppl.6028

DO - 10.1200/JCO.2021.39.15_suppl.6028

M3 - Meeting Abstract

SN - 0732-183X

VL - 39

SP - 6028

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -